Fluidx Medical Technology’s Innovative Embolic Tumor Treating Device Highlighted in “BEST of GEST” Session at the Global Embolization Oncology Symposium Technologies (“GEST”) Conference
August 26, 2021
Fluidx Medical Technology’s GPX Embolic Device was selected for a Global Embolization Oncology Symposium Technologies (“GEST”) “BEST of GEST” session highlighting the technology’s ability to devascularize tumors during minimally-invasive transcatheter embolization procedures (https://gest2021.gestweb.org/program/program/107/oral-abstracts-renal).
“The versatility of the GPX product has been demonstrated in a variety of interventional oncology uses,” said Andrew Holden, M.D., MBChB, FRANZCR, EBIR, ONZM, Director of Interventional Radiology, Auckland City Hospital, Auckland, New Zealand. “We have seen excellent distal penetration and backfilling of larger vessels in our tumor cases. In these cases, GPX provided effective, durable occlusions as confirmed using angiography several weeks post-GPX delivery.”
The GPX Embolic Device is an innovative embolic designed for simple preparation and quick material delivery, as highlighted in case videos at the BEST of GEST event. GPX technology is a low viscosity, aqueous-based solution in a syringe that solidifies into a durable embolus upon delivery without polymerization or dimethyl-sulfoxide (DMSO) precipitation. GPX is designed to occlude blood vessels independent of a patient’s coagulation situation.
GPX is packaged ready-to-use in a syringe, requires less than 1 minute of tableside preparation by the clinician, and may be delivered through standard catheters or small microcatheters (no complex mixing systems or special delivery catheters are necessary). *
Fluidx Medical Technology is a Salt Lake City, Utah based company focused on developing the GPX Embolic Device and other innovative medical technologies. The GPX Embolic Device is under development and does not have marketing clearance or approval in any market at this time. For investigational use (in New Zealand) only.
*Fluidx Medical Technology data on file.
Recent News
- BioUtah’s 2026 Utah Life Sciences Summit Recap
- 2026 Life Sciences Awards to be Presented at the Mayer Brown Utah Life Sciences Summit
- PROGRESS TRIAL DEMONSTRATES EDWARDS TAVR IS SUPERIOR TO CLINICAL SURVEILLANCE FOR MODERATE AS PATIENTS WITH AT-RISK FEATURES
- Denali Therapeutics Receives 2026 Prix Galien USA Award for AVLAYAH® (tividenofusp alfa-eknm) as Best Biotechnology Product
- Utah Business, Government Leaders Deepen Connections in Ireland
- Co-Diagnostics’ Joint Venture CoSara Diagnostics Announces Publication of Peer-Reviewed HPV Screening Study Using CoSara’s SARAGENE® Test
